A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe

FLORENCE, Italy & SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. 

Subscribe to one of our social media channels